878.2500 -3.15 (-0.36%)
NSE Sep 09, 2025 15:31 PM
Volume: 177.6K
 

878.25
-0.36%
Axis Direct
Strides reported Q4'17 EBITDA of Rs 1.56bn, 28% below our expectations, hit by challenging environment across key markets. EBITDA including other income was Rs 2.1 bn, which is ~95% of H2'17 EBITDA guidance.
Promoters unpledged 1.88% of shares in last quarter. Total pledge stands at 50.10% of promoter holdings
More from Strides Pharma Science Ltd.
Recommended